A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Summary

This is a Phase 1, open-label, multicenter, multiple-dose study to evaluate aumolertinib in European participants with a confirmed diagnosis of activating EGFR mutation positive (EGFRm+) locally advanced or metastatic NSCLC.

Timeline

Start

2024-12-05

Primary completion

2025-08-09

Completion

2027-12-31

Drugs

Indications